Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study

Psychiatry Research
Jose MathewsYvette I Sheline

Abstract

In this pilot study we assessed the efficacy of olanzapine as monotherapy in the treatment of major depressive disorder, without psychosis. We also demonstrated the in vivo 5-HT2A receptor occupancy of olanzapine using positron emission tomography. An open-label prospective 6-week study design with 14 patients who met the inclusion and exclusion criteria for the study were enrolled from the general community of the St. Louis metropolitan area. All patients met DSM-IV criteria for major depressive disorder without psychosis, had a Hamilton Depression Rating Scale (HAMD17) score >18 and were between the ages of 18 and 65. The primary measure of efficacy was the change in HAMD 17 total score from baseline to endpoint. The data were collected between 1998 and 2004. There was a significant reduction in the HAMD17 scores from baseline to endpoint. Half the patients (n=6) showed > or =50% reduction in their HAMD17 scores. This study points to the potential of olanzapine as a therapeutic agent for the treatment of major depressive disorder without psychosis.

References

Apr 1, 1992·Journal of Clinical Psychopharmacology·V ArangoJ J Mann
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Apr 1, 1982·Archives of General Psychiatry·N R Schooler, J M Kane
Jan 4, 2001·The American Journal of Psychiatry·R C SheltonH Y Meltzer
Mar 21, 2001·Bipolar Disorders·S N GhaemiF K Goodwin
Mar 1, 2002·The American Journal of Psychiatry·Yvette I ShelineAbraham Z Snyder
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Nov 12, 2003·Archives of General Psychiatry·Mauricio TohenAlan Breier
Jan 28, 2004·The Journal of Clinical Psychiatry·Michael P Bogenschutz, H George Nurnberg
Dec 14, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michael J DetkeIstvan Bitter
Dec 14, 2004·Journal of Psychiatric Research·Stephen K BrannanGary D Tollefson

❮ Previous
Next ❯

Citations

Aug 15, 2013·Cell and Tissue Research·Vincenzo MicaleAlexandra Sulcova
Nov 22, 2011·Expert Opinion on Pharmacotherapy·Michele FornaroGiulio Perugi
Nov 2, 2013·Expert Review of Neurotherapeutics·Richard Weisler, Roger S McIntyre
Mar 16, 2011·CNS Neuroscience & Therapeutics·Thomas L Schwartz, Stephen M Stahl
Feb 28, 2008·International Clinical Psychopharmacology·Stuart A Montgomery
Dec 5, 2006·Current Opinion in Psychiatry·Marek Jarema
Jan 1, 2008·International Journal of Psychiatry in Clinical Practice·Mazda AdliMichael Bauer
Jul 9, 2008·Cognitive Neuropsychology·David Kemmerer, Daniel Tranel
May 6, 2009·Journal of Cognitive Neuroscience·Cristiano CrescentiniEmiliano Macaluso
Nov 26, 2009·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Antoni Rodríguez-FornellsRuth de Diego-Balaguer
Aug 16, 2011·Cognitive, Affective & Behavioral Neuroscience·Sharon M Antonucci, Mary Alt
Aug 25, 2011·Journal of Cognitive Neuroscience·Alexander KranjecAnjan Chatterjee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

International Journal of Cardiology
Puneet KakarS Loganathan
Journal of Psychopharmacology
Patrick KeownAllan Young
Schizophrenia Research
Joshua T KantrowitzCenk Tek
© 2021 Meta ULC. All rights reserved